HBeAg-negative chronic hepatitis

Cite item

Full Text


  1. Magnius L. О., Espmark J. A. New specificities in Australia antigen positive sera distinct from the Le Bouver determinants. J. Immunol. 1972; 109: 1017-1025.
  2. Hadziyannis S. J., Lieberman H. M., Karvountzis G. G., Shafritz D. A. Analysis of liver disease, nuclear HBcAg, viral replication and hepatitis В virus DNA in liver and serum of HBeAg va anti-HBe positive carriers of hepatitis В virus. Hepatology 1983; 3: 656-662.
  3. Bonino F., Rosina F., Rizetto M. et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe Gastroenterology 1986; 90: 1268-1273.
  4. Lok A. S., Heathcote J., Haofnagle J. H. Management of hepatitis B: 2000 - summary recommendations. Gastroenterology 2001; 120: 1828-1853.
  5. Carman W. F., Jacyna M. R., Hadziyannis S. et al. Mutation preventing formation of hepatitis В е antigen in patients with chronic hepatitis В infection. Lancet 1989; 2: 588-591.
  6. Brunette M. R., Stemler M., Bonino F. et al. A new hepatitis В virus strain in patients with severe anti-HBe positive chronic hepatitis B. J. Hepatol. 1990; 10: 258-261.
  7. Okamoto H., Tsuda F., Akahane Y. et al. Hepatitis В virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J. Virol. 1994; 68: 8102-8110.
  8. Hadziyannis S. J. Hepatitis В е antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. J. Viral Hepatit. 1995; 1: 7-36.
  9. Funk M. L., Rosenberg D. M., Lok A. S. F. World-wide epidemiology of HBeAg-negative chronic hepatitis В and asociated precore and core promoter variants. J. Viral Hepatit. 2002; 9: 52-61.
  10. Okamoto H., Yotsumoto Y., Akahane T. et al. Hepatitis В viruses with precore defects prevail in persistently infected hosts along with seroconversion to anti-HBe. J. Virol. 1990; 64: 1298-1303.
  11. Takeda K., Akahane Y., Suzuki H. et al. Defects in the precore region of the HBV genome in patients with chronic hepatitis В after sustained seroconversion from HBeAg to anti-HBe induced spontaneously or with interferon therapy. Hepatology 1990; 12: 1284-1289.
  12. Brunetto M. R., Giarin M., Oliveri F. et al. Wild type and e antigen-minus hepatitis В virus in course of chronic hepatitis. Proc. Natl. Acad. Sci USA 1991; 88: 4186-4190.
  13. Hamasaki K., Nakata K., Nagayama Y. et al. Changes in the prevalence of HBeAg-negative mutant hepatitis В virus during the course of chronic hepatitis B. Hepatology 1994; 20: 8-14.
  14. Papatheodoridis G. V., Hadziyannis S. J. Diagnosis and management of precore mutant chronic hepatitis B. J. Viral Hepatit. 2001; 8: 311-321.
  15. Maruyama Т., Kuwata S., Koike K. et al. Precore wild-type DNA and immune complexes persist in chronic hepatitis В after seroconversion: no association between genome conversion and seroconversion, Hepatology 1998; 27(1): 245-253.
  16. Fattovich G., Rugge M., Brollo L. et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6: 167-172.
  17. Hsu Y. S., Chien R. N., Yeh С. Т. et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-1527.
  18. Hadziyannis S. J., Vassipulos D. Pathogenesis of hepatitis В е antigen negative chronic hepatitis В infection. Antiviral Ther. 2000; 5(suppl. 1): 12808-12812.
  19. Ter Borg F., ten Kate F. J. W., Cuypers H. Т. M. et al. Relation between laboratory test results and histological hepatitis activity in individuls positive for hepatitis В surface antigen and antibodies to hepatitis В e antigen. Lancet 1998; 351: 1914- 1918.
  20. Marmesis E., Papatheodoridis G. V., Sevastianos V. et al. Significance of HBV viremia levels estimated by a quantitative PCR assay in the evalution of HBeAg negative chronic HBV infection. J. Hepatol. 2001; 34(suppl. 1): 115.
  21. Hadziyannis S., Bramou A., Alexopoulou A., Makris A. Immunopathogenesis and natural course of anti-HBe-positive chronic hepatitis with replicating В virus. In: Hollinger F. В., Lemon S. M., Margolis H. S., eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins; 1991. 673-676.
  22. Brunetto M. R., Oliveri F., Rocca G. et al. Natural course and response to interferon of chronic hepatitis В accompanied by antibody to hepatitis В е antigen. Hepatology 1989; 10: 198-202.
  23. Zarski J. P., Marcellin P., Cohard M. et al. Comparison of anti-HBe positive and HBe-antigen-positive chronic hepatitis В in France. J. Hepatol. 1994; 20: 636-640.
  24. Papatheodoridis G. V,, Manesis E., Hadziyannis S. J. The longterm outcome of interferon-a treated and untreated patients with HbeAg-negative chronic hepatitis B. J. Hepatol. 2001; 34: 306-313.
  25. Park Y. N., Han K. H., Kim K. S. et al. Cytoplasmic expression of hepatitis В core antigen in chronic hepatitis В virus infection: role of precore stop mutants. Liver 1999; 19: 199-205.
  26. Chu С. M., Liaw Y. F. Intrahepatic expression of HBcAg in chronic HBV hepatitis: lessons from molecular biology. Hepatology 1990; 12: 1443-1445.
  27. Brunetto M. R., Oliveri F., Coco B. et al. Outcome of anti-HBe positive chronic hepatitis В in alpha-interferon treated and untreated patients: a long term cohort study. J. Hepatol. 2002; 36: 263-270.
  28. Santantonio Т., Jung M. C., Pastore G. et al. Familial clustering of HBV pre-C and pre-S mutants. J. Hepatol. 1997; 26: 221-227.
  29. Di Marco V., Lo lacono O., Camma C. et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257-264.
  30. Fattovich G., Farci P., Rugge M. et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitus В lacking HBeAg. Hepatology 1992; 15: 584-589.
  31. Lampertico P., Del Ninno E., Manz'in A. et al. A randomized, controlled trial of a 24-month course of interferon alpha 2b in patients with chronic hepatitis В who had hepatitis В virus DNA without hepatitis В е antigen in serum. Hepatology 1997; 26: 1621-1625.
  32. Tassopoulos N. C., Volpes R., Pastore G. et al. Efficacy of lamivudine in patients with hepatitis В е antigen-negative/hepatitis В virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-896.
  33. Liaw Y. F., Chu С. M., Lin D. Y. et al. Age-specific prevalence and significance of HBeAg/anti-HBe in chronic HBV infection in Taiwan: a comparison among asymptomatic carries, chronic hepatitis, liver cirrhoris and hepatocellular carcinoma. J. Med. Virol. 1984; 13: 385-391.
  34. Brunetto M. R., Rodriques U. A., Bonino F. Hepatitis В virus mutants. Intervirology 1999; 42: 69-80.
  35. Hadziyannis S. J., Vassilopoutos D. Hepatitis В е antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-624.
  36. Naoumov N. V., Scheider R., Grotzinger T. et al. Precore mutant hepatitis В virus infection and liver diesease. Gastroenterology 1992; 102: 538-543.
  37. Lai M. E., Solinas A., Mazzoleni A. P. et al. The role of precore hepatitis В virus mutants on the long-term outcome of chronic hepatitis В virus hepatitis. A longitudinal study. J. Hepatol. 1994; 20: 773-781.
  38. Fattovich G., Brollo L., Alberti A. at al. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology 1988; 8: 1651-1654.
  39. Pastore G., Santantonio Т., Miella M. et al. Anti-HBe-positive chronic hepatitis В with HBV DNA in the serum: response to a 6-month course of lymphoblastoid interferon. J. Hepatol. 1992; 14: 221-225.
  40. Brunetto M. R., Oliveri F., Colobatto P. et al. Treatment of chronic anti-HBe-positive hepatitis В with interferon-alpha. J. Hepatol. 1995; 22(suppl. 1): 42-44.
  41. Oliveri F., Santantonio Т., Bellati G. et al. Long term response to therapy of chronic anti-HBe-positive hepatitis В is poor indepensent of type and schedule of interferon. Am. J. Gastroen- J terol. 1999; 94: 1366-1372.
  42. Manesis E. K., Hadziyannis S. J. Interferon-alpha treatment and retreatment of hepatitis В е antigen negative chronic hepatitis B. Gastroenterology 2001; 121: 91-100.
  43. Hadziyannis S. J., Papaioannou C., Savas S. et al. Lor£ term alpha-interferon therapy in anti-HBe-positive chronic hepatitis В increases significantly the frequency of sustained response. Hepatology 1994; 19: 701.
  44. Fernandez I., Castellano G., Manzano M. L. et al. Twelve-month interferon-alpha therapy induces a similar sustained response in anti-HBe-positive and HBeAg-positive chronic hepatitis В patients. Hepatogastroenterology 2000; 47(35): 1351 - 1355.
  45. Rizzetto M. Efficacy of lamivudine in HBeAg-negative chronic J hepatitis B. J. Med. Virol. 2002; 66: 435-451. 1
  46. Santantonio Т., Mazzola M., lacovazzi T. et al. Long-term follow-up of patients with ami HBe/HBV DNA-positive chronic hepatitis В treated for 12 months with lamivudine. J. Hepatol. 2000; 32: 300-306.
  47. Donada C., Priva S., Faelli A. et al. Interferon alpha lamivudine in patients with chronic hepatitis В anti-HBe positive. J. Hepatol. 1999; 30(suppl. 1): 246.
  48. Honkoop P., Niesters H. G., de Man R. A., Schalm S. W. Lamivudine resistance in immunocompenetnt chronic hepaptitis B. Incidence and patterns. J. Hepatol. 1997. 26(6): 1393-1395.
  49. Chayama K., Suzuki Y., Kobayashi M. et al. Emergence and J takeover of YMDD motif mutant hepatitis В virus during longterm lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-1716. i
  50. Chang Т. Т., Lai C. L., Liaw Y. F. et al. Incremental increases in HBeAg serocoversion and continued ALT normalisation in Asian chronic HBV (CHB) patients treated with lamivudine for four years. Antiviral Ther. 2000; 5(suppl. 1): 44. |
  51. Hadziyannis S. J., Papatheodoridis G. V., Dimou E. et al. Efficacy of longterm lamivudine monotherapy in patients with HBeAg negative chronic hepatitis B. Hepatology 2000; 32: 847-851.
  52. Liaw Y.-E., Leung N. W. Y., Chang Т. Т. et al. Effects of extended lamivudme therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-180.
  53. Lau D. T. Y., Khokhar P., Doo E. et al. Long-term therapy of chronic hepatitis В with lamivudine. Hepatology 2000; 32: 828-834.
  54. Papatheodoridis G. V., Dimou E. Papadimitropoulose V. Course of virologic breakthroughs under lamivudine therapy in patients with precore mutants HBV related chronic liver disease. Gastroenterology 2001; 120(suppl.): A385.
  55. Papatheodoridis G. V., Dimou E., Rapti I. et al. HBV reactivation and biochemical breakthroughs after initialy effective lamivudine therapy in patients with precore mutants HBV related liver disease. Hepatology 2000; 32: 375A.
  56. Tatulli I., Francavilla R., Luca Rizzo G. et al. Lamivudine and alphainterferon in combination long term for precore mutant chronic hepatitis B. J. 2001; 35: 805-810.
  57. Sanantonio Т., Niro G. A., Sinisi E. et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatits B: a controlled pilot study. J. Hepatol. 2002; 36: 799-804.
  58. Yalcin K., Yildiz E., Degertekin H., Celik Y. А 12 months course of interferon and lamivudine combination therapy versus interferon monotherapy for untreated chronic hepatitis В infection. J. Hepatol. 2002; 36: 494.
  59. Cinar K., Sarioglu M., Cetinkaya H. et al. Predictive value of ALT and HBV DNA levels in response to sequential combination treatment of lamivudine and interferon in HBeAg-/antiHBe+ chronic hepatitis B. J. Hepatol. 2002; 36: 367.

Copyright (c) 2004 Ibragimova M.M., Krel P.E., Abdurakhmanov D.T.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies